Evotec (ETR:EVT) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Evotec SE (ETR:EVT) shares crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of €2.90 and traded as high as €3.17. Evotec shares last traded at €3.09, with a volume of 2,451,951 shares.

Evotec Price Performance

The company has a quick ratio of 2.97, a current ratio of 2.33 and a debt-to-equity ratio of 71.50. The firm has a market capitalization of $587.06 million, a price-to-earnings ratio of -3.42, a P/E/G ratio of 0.98 and a beta of 1.27. The company’s 50 day moving average is €2.90 and its 200 day moving average is €4.34.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.